Search results for Farletuzumab ELISA Kit
Farletuzumab ELISA Kit, ProteoGenix, KPTX185
Description of Farletuzumab ELISA Kit Introduction to Farletuzumab ELISA Kit Farletuzumab is a humanized monoclonal antibody that specifically targets the folate receptor alpha (FRα). This receptor is overexpressed in a variety of solid tumors, making it a promising therapeutic target for cancer treatment. The Farletuzumab ELISA Kit is a powerful tool for detecting and quantifying this antibody in biological samples. In this article, we will discuss the structure, activity, and application of the Farletuzumab ELISA Kit. Structure of Farletuzumab ELISA Kit The Farletuzumab ELISA Kit is composed of several components, including a microplate coated with FRα antigen, a standard solution of known concentration of Farletuzumab, and detection reagents. The microplate is typically made of polystyrene and is divided into multiple wells, each of which can accommodate a small volume of the sample. The FRα antigen is immobilized on the surface of the microplate, allowing for specific binding of Farletuzumab. Activity of Farletuzumab ELISA Kit The activity of the Farletuzumab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA). This technique utilizes the specific binding of an antibody to its target antigen, which is then detected using an enzyme-linked secondary antibody. In the case of the Farletuzumab ELISA Kit, the primary antibody is Farletuzumab and the secondary antibody is conjugated to an enzyme such as horseradish peroxidase (HRP). When the sample is added to the microplate, any Farletuzumab present in the sample will bind to the FRα antigen on the plate. The addition of the HRP-conjugated secondary antibody and a substrate for the enzyme will result in a color change, which can be measured using a spectrophotometer. The intensity of the color is directly proportional to the amount of Farletuzumab present in the sample, allowing for accurate quantification. Application of Farletuzumab ELISA Kit The Farletuzumab ELISA Kit has a wide range of applications in both research and clinical settings. It is commonly used to measure the levels of Farletuzumab in serum, plasma, and other biological samples. This can provide valuable information about the pharmacokinetics and pharmacodynamics of the antibody, as well as its potential efficacy as a therapeutic agent. Additionally, the Farletuzumab ELISA Kit can be used to monitor the response of patients to Farletuzumab treatment, as well as to assess the presence of anti-drug antibodies that may affect treatment efficacy. Furthermore, the Farletuzumab ELISA Kit can also be used in the development of new therapeutic agents targeting FRα. By measuring the binding affinity and specificity of potential drugs to FRα using the Farletuzumab ELISA Kit, researchers can identify promising candidates for further development. Conclusion In summary, the Farletuzumab ELISA Kit is a valuable tool for detecting and quantifying Farletuzumab, a promising therapeutic antibody targeting FRα. Its structure, activity, and application make it an essential component in the development and evaluation of Farletuzumab-based therapies. With its high sensitivity and specificity, the Farletuzumab ELISA Kit is a crucial asset in the fight against cancer and the search for new and effective treatments.
Host
Reactivity
Applications
Conjugation
Farletuzumab ELISA Kit, Abbexa, abx395074
Farletuzumab ELISA Kit is a quantitative ELISA kit for detection of Farletuzumab.Farletuzumab (MORAb-003) is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012). In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012). Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months (Konner et al., 2010). Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013). The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ≥ 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab (MEDI4736).
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.